Literature DB >> 8968558

Effects of adrenomedullin and calcitonin gene-related peptide on airway and pulmonary vascular smooth muscle in guinea-pigs.

A Pinto1, K Sekizawa, M Yamaya, T Ohrui, Y X Jia, H Sasaki.   

Abstract

1. The airway and pulmonary vascular effects of adrenomedullin were studied in the guinea-pig isolated trachea, main bronchi and pulmonary artery in vitro and compared to the effects of calcitonin gene-related peptide (CGRP). 2. In tracheal rings, CGRP (1 nM to 1 microM) potentiated the cholinergic contractions induced by electrical field stimulation (EFS) at 5 Hz in a concentration-dependent manner. At a concentration of 1 microM, CGRP slightly decreased the responses to log EFS frequency, producing 50% of the maximum contraction from a control value of 0.77 +/- 0.10 Hz to 0.54 +/- 0.05 Hz without a significant effect on the concentration-response curves to acetylcholine (ACh). In contrast, adrenomedullin (1 nM to 1 microM) did not alter either EFS-induced cholinergic or ACh-induced contractions. 3. In bronchial strips, CGRP (1 nM to 1 microM) slightly reduced both the non-adrenergic non-cholinergic (NANC) contraction induced by EFS at 10 Hz and the substance P (1 microM)-induced contraction in a concentration-dependent manner, whereas adrenomedullin (1 nM to 1 microM) was without effect. 4. Neither CGRP (1 microM) nor adrenomedullin (1 microM) altered NANC relaxation induced by EFS at 5 Hz in tracheal rings precontracted with histamine (10 microM). 5. Adrenomedullin (1 nM to 1 microM) and CGRP (1 nM to 1 microM) induced a concentration-dependent relaxation of the histamine (10 microM)- and prostaglandin F2 alpha (10 microM)-precontracted pulmonary arterial rings with intact endothelium with a similar potency. 6. Neither removal of the endothelium nor NG-nitro-L-arginine methyl ester (100 microM) altered the vasorelaxant effects of adrenomedullin (1 nM to 1 microM) and CGRP (1 nM to 1 microM). 7. The putative CGRP receptor antagonist, CGRP8-37 (1 microM to 10 microM) concentration-dependently attenuated the CGRP (3 nM to 30 nM)-induced vasorelaxant actions, whereas it had no effect on the relaxation of vessel rings induced by adrenomedullin (3 nM to 30 nM). 8. These results suggest that adrenomedullin is a potent vasodilator of the pulmonary artery without any bronchomotor effect in the guinea-pig lung, and that the vasorelaxant actions of adrenomedullin are not mediated via the activation of CGRP1 receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968558      PMCID: PMC1915818          DOI: 10.1111/j.1476-5381.1996.tb16061.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

1.  Adrenotensin: an ADM gene product with the opposite effects of ADM.

Authors:  B Gumusel; J K Chang; A Hyman; H Lippton
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

2.  The effects of IAPP and CGRP on guinea pig tracheal smooth muscle in vitro.

Authors:  R Bhogal; R L Sheldrick; R A Coleman; D M Smith; S R Bloom
Journal:  Peptides       Date:  1994       Impact factor: 3.750

3.  Vasoactive intestinal peptide: a possible transmitter of nonadrenergic relaxation of guinea pig airways.

Authors:  Y Matsuzaki; Y Hamasaki; S I Said
Journal:  Science       Date:  1980-12-12       Impact factor: 47.728

4.  Pulmonary vasodilation to adrenomedullin: a novel peptide in humans.

Authors:  J Heaton; B Lin; J K Chang; S Steinberg; A Hyman; H Lippton
Journal:  Am J Physiol       Date:  1995-06

5.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.

Authors:  R F Furchgott; J V Zawadzki
Journal:  Nature       Date:  1980-11-27       Impact factor: 49.962

6.  An adrenomedullin (ADM) fragment retains the systemic vasodilator activity of human ADM.

Authors:  Q Hao; J K Chang; H Gharavi; Y Fortenberry; A Hyman; H Lippton
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

7.  Comparative effects of adrenomedullin, an adrenomedullin analog, and CGRP in the pulmonary vascular bed of the cat and rat.

Authors:  B D Nossaman; C J Feng; D Y Cheng; B J Dewitt; D H Coy; W A Murphy; P J Kadowitz
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

8.  Effects of calcitonin gene-related peptide receptor antagonists on renal actions of adrenomedullin.

Authors:  A M Elhawary; J Poon; C C Pang
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

9.  Regional haemodynamic effects of human and rat adrenomedullin in conscious rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

10.  Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats.

Authors:  Y Ishiyama; K Kitamura; Y Ichiki; S Nakamura; O Kida; K Kangawa; T Eto
Journal:  Eur J Pharmacol       Date:  1993-09-14       Impact factor: 4.432

View more
  4 in total

Review 1.  The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors.

Authors:  Debbie L Hay; Alex C Conner; Stephen G Howitt; David M Smith; David R Poyner
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

2.  Influence of CGRP (8-37), but not adrenomedullin (22-52), on the haemodynamic responses to lipopolysaccharide in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

3.  Calcitonin gene-related peptide hyperpolarizes mouse pulmonary artery endothelial tubes through KATP channel activation.

Authors:  Charles E Norton; Steven S Segal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-03-15       Impact factor: 5.464

4.  Biochemical, Anatomical, and Pharmacological Characterization of Calcitonin-Type Neuropeptides in Starfish: Discovery of an Ancient Role as Muscle Relaxants.

Authors:  Weigang Cai; Chan-Hee Kim; Hye-Jin Go; Michaela Egertová; Cleidiane G Zampronio; Alexandra M Jones; Nam Gyu Park; Maurice R Elphick
Journal:  Front Neurosci       Date:  2018-06-08       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.